MetaVia Inc. (NASDAQ: MTVA) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The company’s stated mission is to transform cardiometabolic diseases by discovering and developing therapies that target key metabolic pathways. Its pipeline is built around multiple drug candidates at different stages, spanning early development through Phase 2a. A ...MetaVia Inc. (NASDAQ: MTVA) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The company’s stated mission is to transform cardiometabolic diseases by discovering and developing therapies that target key metabolic pathways. Its pipeline is built around multiple drug candidates at different stages, spanning early development through Phase 2a.
A central program is DA-1241, a unique G-Protein-Coupled Receptor 119 agonist. According to the provided company overview, DA-1241 has completed Phase 1 trials for type 2 diabetes mellitus (T2DM) and is advancing in Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). The company positions this candidate as potentially useful both as a standalone therapy and as part of combination regimens—an approach commonly used in metabolic and liver disease indications to improve efficacy while tailoring patient response.
MetaVia’s other major development asset is DA-1726, described as an oxyntomodulin analogue and a dual GLP-1/glucagon receptor agonist. DA-1726 is in preclinical development with a focus on obesity, reflecting the company’s emphasis on addressing disorders with significant unmet medical need and that often benefit from receptor-pathway modulation.
Beyond these primary programs, MetaVia also references a broader pipeline including ANA001 (an oral niclosamide formulation intended for moderate COVID-19 patients), NB-01 (for painful diabetic neuropathy), NB-02 (for cognitive impairment), and Gemcabene (for dyslipidemia). The inclusion of multiple therapeutic areas underscores that the company operates as a platform-style developer, pursuing several internal candidates while also leveraging strategic relationships.
In terms of partnerships and business model, MetaVia has highlighted a licensing agreement with Pfizer Inc. related to Gemcabene across research, development, manufacturing, and commercialization. The company also cites joint research collaborations (e.g., involving Dong-A ST and ImmunoForge) supporting the advancement of DA-1726. These collaborations can reduce development risk and help fund or accelerate specific programs—an important consideration for small, clinical-stage biopharma companies.
From a financial and operational perspective, the provided data suggests MetaVia is a very small organization (employee count referenced in the single digits to low tens; overall size class 0–100). As a clinical-stage biotech, it typically requires substantial cash to advance trials, scale regulatory work, and support manufacturing readiness, and therefore may not yet have meaningful revenues. The company’s valuation and profitability metrics in the provided dataset appear consistent with early-stage biotech economics (i.e., limited or negative earnings), while balance sheet measures indicate it maintains liquidity.
Key leadership includes CEO and President Hyung Heon Kim (in role since 2023 per the provided information). As MetaVia is still building its clinical programs, future “wishes” for the business likely center on successful trial readouts for DA-1241 and DA-1726, advancing additional assets through the clinic, expanding or optimizing partnerships, and continuing to strengthen its pipeline while maintaining sufficient funding to support trial milestones.
